Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives

Author(s): Lara Alessandrini , Tiziana Perin , Shahin Kadare , Lino del Pup , Lorenzo Memeo , Agostino Steffan , Lorenzo Colarossi , Massimiliano Berretta , Paolo De Paoli , Vincenzo Canzonieri* .

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 5 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features.

More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor.

This review focuses on the pathologist’s role in carefully controlling pre- analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist's perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.

Keywords: Target therapy, biomarker, pathologist's perspective, Immunohistochemistry, FFPE tissue, molecular analyses, traditional sequencing, next-generation sequencing.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2018
Page: [410 - 420]
Pages: 11
DOI: 10.2174/1568009618666171129145703
Price: $58

Article Metrics

PDF: 24
HTML: 4